Please assess the completion status of the following clinical trial:

Trial Title: TMC114-TiDP3-C176 - A Study in Healthy Volunteers Investigating the Bioequivalence Between Two Commercially Available 400-mg Tablets to One New 800-mg Tablet of Darunavir (DRV) in the Presence of Low-dose Ritonavir Under Fed and Fasted Conditions

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy based on a medical evaluation including medical history, physical examination, blood tests and electrocardiogram~* Body Mass Index of 18.0 to 30.0 kg/m² and non-smoker or smoking no more than 10 cigarettes, or 2 cigars, or 2 pipes per day for at least 3 months~* Women must be postmenopausal for at least 2 years or be surgically sterile or be not heterosexually active for the duration of the study or have a vasectomized partner~* Men must agree to use a highly effective method of birth control.~Exclusion Criteria:~* Infection with Hepatitis A, B, or C virus~* infection with HIV~* Women who are pregnant or breastfeeding~* History of, or any current medical condition which could impact the safety of the participant in the study~* Previously participated in a multiple-dose study with DRV.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 001 (Type: EXPERIMENTAL): Darunavir (DRV) 2x400-mg DRV tablet or 800-mg tablet on Day 3
- 002 (Type: EXPERIMENTAL): ritonavir 100-mg once daily on Day 1 to Day 5

Based on this trial design, predict the completion outcome and termination type (if applicable).